+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Generics in the United States - Market Summary, Competitive Analysis and Forecast to 2025

  • PDF Icon

    Report

  • 40 Pages
  • July 2021
  • Region: United States
  • MarketLine
  • ID: 5397512
Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights
  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The US generics market had total revenues of $110.2bn in 2020, representing a compound annual growth rate (CAGR) of 2% between 2016 and 2020.
  • Market consumption volume increased with a CAGR of 0.3% between 2016 and 2020, to reach a total of 90.0% in 2020.
  • Growth in the generics market has been driven by the rising elderly population, due to an increase in age-associated disease, such as diabetes and cardiovascular diseases, increased access to healthcare services, high disease burden, and launch of new products during the historic period.

Scope
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United States
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts

Reasons to Buy
  • What was the size of the United States generics market by value in 2020?
  • What will be the size of the United States generics market in 2025?
  • What factors are affecting the strength of competition in the United States generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up the United States's generics market?
Frequently Asked Questions about the Generics Market in the United States

What is the estimated value of the Generics Market in the United States?

The Generics Market in the United States was estimated to be valued at $110.22 Billion in 2020.

What is the growth rate of the Generics Market in the United States?

The growth rate of the Generics Market in the United States is 2.4%, with an estimated value of $124.14 Billion by 2025.

What is the forecasted size of the Generics Market in the United States?

The Generics Market in the United States is estimated to be worth $124.14 Billion by 2025.

Who are the key companies in the Generics Market in the United States?

Key companies in the Generics Market in the United States include Teva Pharmaceutical Industries Limited and Pfizer Inc..

Table of Contents

1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the COVID-19 pandemic impacted leading players?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Pfizer Inc.
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related Research
10.4. About the Author
List of Tables
Table 1: United States generics market value: $ billion, 2016-20
Table 2: United States generics market volume: %, 2016-20
Table 3: United States generics market geography segmentation: $ billion, 2020
Table 4: United States generics market value forecast: $ billion, 2020-25
Table 5: United States generics market volume forecast: %, 2020-25
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 16: Pfizer Inc.: key facts
Table 17: Pfizer Inc.: Annual Financial Ratios
Table 18: Pfizer Inc.: Key Employees
Table 19: Pfizer Inc.: Key Employees Continued
Table 20: United States size of population (million), 2016-20
Table 21: United States gdp (constant 2005 prices, $ billion), 2016-20
Table 22: United States gdp (current prices, $ billion), 2016-20
Table 23: United States inflation, 2016-20
Table 24: United States consumer price index (absolute), 2016-20
Table 25: United States exchange rate, 2016-20
List of Figures
Figure 1: United States generics market value: $ billion, 2016-20
Figure 2: United States generics market volume: %, 2016-20
Figure 3: United States generics market geography segmentation: % share, by value, 2020
Figure 4: United States generics market value forecast: $ billion, 2020-25
Figure 5: United States generics market volume forecast: %, 2020-25
Figure 6: Forces driving competition in the generics market in the United States, 2020
Figure 7: Drivers of buyer power in the generics market in the United States, 2020
Figure 8: Drivers of supplier power in the generics market in the United States, 2020
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2020
Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2020
Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Pfizer Inc.